Opsoclonus-Myoclonus-Associated Neuroblastoma With Bone Marrow Metastases: What Would Be the Best Treatment Option?

Oncology (Williston Park). 2021 Oct 22;35(10):665-667. doi: 10.46883/ONC.2021.3510.0665.

Abstract

A 1.9-year-old girl was presented to the hospital with dancing eye movements, ataxia, and behavioral disorders. The MRI showed a retroperitoneal tumor (transversal size: 3.9 x 2.5 cm, craniocaudal size: 4.6 cm) extending from T12 to L3 vertebral bodies (Figure), which was suspicious for neuroblastoma. Afterwards, biopsy of the lesion and bone marrow was performed. The initial pathological evaluation (CD56+, PHOX2B+, NKX2-, Ki67 50%-55%, NSE+, CD99-) of the tumor and bone marrow confirmed the diagnosis of poorly differentiated, high-risk neuroblastoma.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Bone Marrow Neoplasms / secondary*
  • Female
  • Humans
  • Infant, Newborn
  • Neuroblastoma / complications*
  • Neuroblastoma / pathology*
  • Neuroblastoma / physiopathology
  • Opsoclonus-Myoclonus Syndrome / drug therapy
  • Opsoclonus-Myoclonus Syndrome / etiology*
  • Opsoclonus-Myoclonus Syndrome / physiopathology

Substances

  • Antineoplastic Agents